Otsuka to fight Delamanid setback after CHMP red light
This article was originally published in Scrip
Executive Summary
Otsuka has suffered a setback after the European Medicines Agency' s Committee for Medicinal Products for Human Use (CHMP) declined to recommend the firm's Delamanid for multi-drug resistant TB. The committee said that the benefits of the drug had not been adequately shown.